Literature DB >> 16513365

Chronic exposure to Delta9-tetrahydrocannabinol downregulates oxytocin and oxytocin-associated neurophysin in specific brain areas.

Elena Butovsky1, Ana Juknat, Judith Elbaz, Maytal Shabat-Simon, Raya Eilam, Abraham Zangen, Miriam Altstein, Zvi Vogel.   

Abstract

Cannabinoids are widely abused drugs. Our goal was to identify genes modulated by Delta9-tetrahydrocannabinol (Delta9-THC) treatment. We found that chronic administration of Delta9-THC (1.5 mg/kg/day, i.p.; 7 days) to rats, downregulates the expression of oxytocin-neurophysin (OT-NP) mRNA and of OT and oxytocin-associated NP (NPOT) immunoreactivity in nucleus accumbens (NAc) and ventral tegmental area (VTA), brain areas involved in reward and addiction. Real-time PCR revealed a 60% and 53% reduction of OT-NP mRNA in NAc and VTA, respectively, under chronic treatment, while no changes were observed in NAc after 24 h. Immunohistochemistry showed a large decrease in number of OT and NPOT-stained fibers in NAc (by 59% and 52%, respectively) and VTA (by 50% and 56%, respectively). No changes in cell staining were observed in the paraventricular nucleus and supraoptic nucleus. As OT is known to inhibit development of drug tolerance and attenuate withdrawal symptoms, we suggest that OT downregulation could play a role during the establishment of the chronic effects of Delta9-THC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513365     DOI: 10.1016/j.mcn.2006.01.008

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  24 in total

Review 1.  Endocannabinoids and the Endocrine System in Health and Disease.

Authors:  Cecilia J Hillard
Journal:  Handb Exp Pharmacol       Date:  2015

2.  Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention.

Authors:  Brian J Sherman; Nathaniel L Baker; Aimee L McRae-Clark
Journal:  Psychiatry Res       Date:  2017-01-20       Impact factor: 3.222

Review 3.  Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date.

Authors:  Mary R Lee; Matthew C H Rohn; Gianluigi Tanda; Lorenzo Leggio
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

Review 4.  Oxytocin for the treatment of drug and alcohol use disorders.

Authors:  Mary R Lee; Elise M Weerts
Journal:  Behav Pharmacol       Date:  2016-12       Impact factor: 2.293

5.  Compartmentalization of endocannabinoids into lipid rafts in a microglial cell line devoid of caveolin-1.

Authors:  Neta Rimmerman; Heather B Bradshaw; Ewa Kozela; Rivka Levy; Ana Juknat; Zvi Vogel
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

6.  Transcriptomic and proteomic analyses of mouse cerebellum reveals alterations in RasGRF1 expression following in vivo chronic treatment with delta 9-tetrahydrocannabinol.

Authors:  Graziano Colombo; Francesco Rusconi; Tiziana Rubino; Angela Cattaneo; Enzo Martegani; Daniela Parolaro; Angela Bachi; Renata Zippel
Journal:  J Mol Neurosci       Date:  2008-06-27       Impact factor: 3.444

7.  Cannabis reward: biased towards the fairer sex?

Authors:  I S McGregor; J C Arnold
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

Review 8.  Early adverse experience and substance addiction: dopamine, oxytocin, and glucocorticoid pathways.

Authors:  Sohye Kim; Stephanie Kwok; Linda C Mayes; Marc N Potenza; Helena J V Rutherford; Lane Strathearn
Journal:  Ann N Y Acad Sci       Date:  2016-08-10       Impact factor: 5.691

Review 9.  Neuropeptidergic regulation of pair-bonding and stress buffering: Lessons from voles.

Authors:  Kyle Gobrogge; Zuoxin Wang
Journal:  Horm Behav       Date:  2015-09-01       Impact factor: 3.587

Review 10.  From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?

Authors:  I S McGregor; P D Callaghan; G E Hunt
Journal:  Br J Pharmacol       Date:  2008-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.